Empagliflozin Induced Pancreatitis

Authors' Affiliations

Jeff Thompson, Department of Internal Medicine, East Tennessee State University, Johnson City, TN. Taif Khattak, Department of Internal Medicine, East Tennessee State University, Johnson City, TN. Divya Agarwal, Quillen College of Medicine, East Tennessee State University, Johnson City, TN. Sharlet Slough, Department of Internal Medicine, East Tennessee State University, Johnson City, TN.

Location

Culp Center Ballroom

Start Date

4-25-2023 9:00 AM

End Date

4-25-2023 11:00 AM

Poster Number

77

Faculty Sponsor’s Department

Internal Medicine

Name of Project's Faculty Sponsor

Sharlet Slough

Classification of First Author

Medical Resident or Clinical Fellow

Competition Type

Competitive

Type

Poster Presentation

Project's Category

Endocrine System

Abstract or Artist's Statement

Since the introduction of Sodium-glucose cotransporter 2 (SGLT2) inhibitors as guideline therapy for both uncontrolled type 2 diabetes mellitus and heart failure, these medications have become popular options as add-on therapy. This class of medication reduces blood glucose levels via inhibition of glucose reabsorption in the proximal convoluted tubules leading to enhanced renal excretion. Not only do SGLT2 inhibitors provide advantages in improved glucose control, but also have proven to reduce cardiovascular mortality. Generally, SGLT2 inhibitors are well tolerated, however adverse reactions of genitourinary tract infections secondary to glucosuria and hypotension from associated osmotic diuresis have been reported. Less commonly, pancreatitis has been associated with use of SGL2 inhibitors. We present a case of suspected empagliflozin induced pancreatitis notable for delayed onset at approximately 120 days since SGLT2 inhibitor initiation.

This document is currently not available here.

Share

COinS
 
Apr 25th, 9:00 AM Apr 25th, 11:00 AM

Empagliflozin Induced Pancreatitis

Culp Center Ballroom

Since the introduction of Sodium-glucose cotransporter 2 (SGLT2) inhibitors as guideline therapy for both uncontrolled type 2 diabetes mellitus and heart failure, these medications have become popular options as add-on therapy. This class of medication reduces blood glucose levels via inhibition of glucose reabsorption in the proximal convoluted tubules leading to enhanced renal excretion. Not only do SGLT2 inhibitors provide advantages in improved glucose control, but also have proven to reduce cardiovascular mortality. Generally, SGLT2 inhibitors are well tolerated, however adverse reactions of genitourinary tract infections secondary to glucosuria and hypotension from associated osmotic diuresis have been reported. Less commonly, pancreatitis has been associated with use of SGL2 inhibitors. We present a case of suspected empagliflozin induced pancreatitis notable for delayed onset at approximately 120 days since SGLT2 inhibitor initiation.